In cancer, allergy and arthritis, the supporting cells drive the disease

Pancreatic cancer: fibroblasts that help the immune system

In pancreatic cancer, a new preprint finds the immune response runs partly through fibroblasts. Fibroblasts that display MHC class II molecules — the machinery for presenting antigens — promote antitumor immunity, and their numbers rise when interferon-gamma-producing CD4 T cells are present. Regulatory T cells suppress them by inhibiting those CD4 responses. The key result: MHC class II expression on fibroblasts is required for CD4 T cell-mediated control of pancreatic cancer progression. The stroma is not just scaffolding; in this setting it is part of the immune response. m:…8882

The dynamic has three players, and each one pulls in a different direction. Interferon-gamma-producing CD4 T cells increase the helpful fibroblasts; regulatory T cells suppress them by shutting down those CD4 cells; and the fibroblasts themselves, when they display MHC class II, are required for the CD4 cells to control the tumour. Remove any leg of that triangle and the control fails. That is a more complicated target than a single receptor, but it is also a more honest picture of how the tumour microenvironment actually works — a negotiation between cell types, not a switch. m:…8882

Allergy: fibroblasts that keep the memory alive

In allergy, the same kind of circuit does the opposite job: it keeps the disease going. Allergic memory in barrier tissues shifts from a type-2 response toward a type-1 profile, marked by interferon signalling and cytotoxic lymphocyte recruitment, and CD8 tissue-resident memory T cells are the primary drivers of that shift. Fibroblasts amplify the recall through an IL-15 and CCL19-dependent circuit with those CD8 cells — and the circuit is conserved in human atopic dermatitis. That conservation is what makes the circuit interesting as a target, and it helps explain why some atopic dermatitis resists therapies aimed only at the type-2 response. m:…1292

Arthritis: the switch from risk to disease

In rheumatoid arthritis, the circuit is a switch. Sustained overexpression of IL-23 in mice converts a mild collagen-induced arthritis into a highly penetrant disease, and the transition depends on IL-17A: neutralizing IL-17A prevents arthritis from developing in the IL-23-overexpressing mice. The human data points the same way. IL-23 receptor, IL-23A and CCR2 expression is increased in rheumatoid arthritis synovium compared with controls, with IL-23 receptor expression higher in early disease than in established disease, and lower RORC and KLRB1 expression in whole blood is associated with a higher risk of onset. The window for intervention, in other words, is before the disease is established — while the IL-23 signal is at its loudest. m:…8834

The timing detail is the part that changes decisions. IL-23 receptor expression is higher in early rheumatoid arthritis than in established disease, and lower RORC and KLRB1 in blood marks a higher risk of onset — which means the pathway is loudest exactly when the disease is still becoming itself. A drug that blocks IL-23 or IL-17A after the disease is established is treating a different problem from one given to a high-risk person before onset. The mouse result — neutralizing IL-17A prevents arthritis in IL-23-overexpressing mice — is a prevention result, not a treatment result, and it should be read that way. m:…8834

One pattern, three diseases

Three diseases, three circuits, one pattern: the cells around the diseased tissue are not bystanders. In pancreatic cancer they can be recruited to help; in allergy they entrench the memory; in arthritis they license the transition from risk to disease. The therapeutic implication is the same in each case — the target is the conversation, not just the cell that carries the disease. That is a harder drug to design than a single-receptor blocker, but it is also where the leverage is. m:…8882 m:…1292 m:…8834